Pharmaceuticals India

India Gene Therapy for Hemophilia Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

India Gene Therapy for Hemophilia Market Industry Trends and Forecast to 2034: Segmented by (Type, Vector, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $6.9 Mn Placeholder estimate
Estimate 2025 $9.2 Mn 1.8% of the global market
Projected 2034 $122.8 Mn 1,228.8% Adds $113.5 Mn over 9 forecast years
CAGR 2025–2034 33.3% Faster than 97% of 180 Pharmaceuticals markets here
Key players 5
  • India is 1.82% of the global market.
  • In APAC, the largest is China at $43.6 Mn.
  • Fastest growing: India (this report) at 33.3% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$113.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Gene Therapy for Hemophilia Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $6.9 Mn — —
2025 (base) $9.2 Mn +$2.3 Mn —
2026 (forecast) $12.3 Mn +$3.1 Mn +33.3%
2027 (forecast) $16.4 Mn +$4.1 Mn +77.7%
2028 (forecast) $21.9 Mn +$5.5 Mn +136.9%
2029 (forecast) $29.2 Mn +$7.3 Mn +215.7%
2030 (forecast) $38.9 Mn +$9.7 Mn +320.9%
2031 (forecast) $51.8 Mn +$12.9 Mn +461%
2032 (forecast) $69.1 Mn +$17.3 Mn +647.8%
2033 (forecast) $92.1 Mn +$23.0 Mn +896.9%
2034 (forecast) $122.8 Mn +$30.7 Mn +1,228.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Gene Therapy for Hemophilia Market Analysis at a glance
Market size, 2025$9.2 Mn placeholder estimate
Forecast, 2034$122.8 Mn placeholder estimate
Growth (CAGR), 2025–203433.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, vector and end user (see all)
Key playersBioMarin, CSL Behring, Pfizer Inc., Roche, Sangamo Therapeutics (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Gene Therapy for Hemophilia Market Analysis Executive Summary

Gene therapies for hemophilia give patients a working copy of the clotting factor gene, so they may need fewer or no regular infusions.

Key segments of the gene Therapy for Hemophilia market include type (Hemophilia A and Hemophilia B) and vector (AAV5 and AAV Other Serotypes).

Bar chart: India Gene Therapy for Hemophilia market size, 2024–2034, placeholder estimates. $6.9 Mn in 2024, $9.2 Mn in 2025 and $122.8 Mn in 2034, 33.3% CAGR.
India Gene Therapy for Hemophilia market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Gene Therapy for Hemophilia Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Therapy for Hemophilia market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Therapy for Hemophilia market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Gene Therapy for Hemophilia Market in India

The gene Therapy for Hemophilia market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Gene Therapy for Hemophilia Market in India

Gene Therapy for Hemophilia in India: rules and payment

New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Therapy for Hemophilia. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Gene Therapy for Hemophilia right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Gene Therapy for Hemophilia in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 12th highest of the 17 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 13th highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 13th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Gene Therapy for Hemophilia market in India?
Placeholder estimate: about $9.2 Mn in 2025, rising to about $122.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Gene Therapy for Hemophilia market in India growing?
Placeholder estimate: about 33.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Gene Therapy for Hemophilia market report cover?
The report splits the market by type (Hemophilia A, Hemophilia B), vector (AAV5, AAV Other Serotypes) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Gene Therapy for Hemophilia market?
Key players include BioMarin, CSL Behring, Pfizer Inc., Roche and Sangamo Therapeutics.
What is driving the Gene Therapy for Hemophilia market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
Who regulates Gene Therapy for Hemophilia in India?
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How much research is published on Gene Therapy for Hemophilia?
PubMed lists 291 papers on Gene Therapy for Hemophilia added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in India

See all

Related on cell and gene therapy and rare diseases

See the topic